JP6353899B2 - ロイコトリエン生成の阻害剤 - Google Patents

ロイコトリエン生成の阻害剤 Download PDF

Info

Publication number
JP6353899B2
JP6353899B2 JP2016527007A JP2016527007A JP6353899B2 JP 6353899 B2 JP6353899 B2 JP 6353899B2 JP 2016527007 A JP2016527007 A JP 2016527007A JP 2016527007 A JP2016527007 A JP 2016527007A JP 6353899 B2 JP6353899 B2 JP 6353899B2
Authority
JP
Japan
Prior art keywords
alkyl
group
pyrazol
yloxy
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016527007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525113A5 (enExample
JP2016525113A (ja
Inventor
アシタ アベイワルデイン
アシタ アベイワルデイン
ジョン アラン ブロードウォーター
ジョン アラン ブロードウォーター
高橋　秀典
秀典 高橋
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2016525113A publication Critical patent/JP2016525113A/ja
Publication of JP2016525113A5 publication Critical patent/JP2016525113A5/ja
Application granted granted Critical
Publication of JP6353899B2 publication Critical patent/JP6353899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016527007A 2013-07-15 2014-07-14 ロイコトリエン生成の阻害剤 Active JP6353899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846137P 2013-07-15 2013-07-15
US61/846,137 2013-07-15
PCT/US2014/046489 WO2015009609A1 (en) 2013-07-15 2014-07-14 Inhibitors of leukotriene production

Publications (3)

Publication Number Publication Date
JP2016525113A JP2016525113A (ja) 2016-08-22
JP2016525113A5 JP2016525113A5 (enExample) 2017-08-31
JP6353899B2 true JP6353899B2 (ja) 2018-07-04

Family

ID=51261274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016527007A Active JP6353899B2 (ja) 2013-07-15 2014-07-14 ロイコトリエン生成の阻害剤

Country Status (4)

Country Link
US (1) US9303018B2 (enExample)
EP (1) EP3022193B1 (enExample)
JP (1) JP6353899B2 (enExample)
WO (1) WO2015009609A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2016000127A1 (en) 2013-12-20 2017-10-06 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors.
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918092A (en) 1983-12-21 1990-04-17 Merck Frosst Canada, Inc. Leukotriene antagonists
US5120758A (en) 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors
DE4127849A1 (de) 1991-08-22 1993-02-25 Merck Patent Gmbh Benzodioxanderivate
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6506876B1 (en) 1994-10-11 2003-01-14 G.D. Searle & Co. LTA4 hydrolase inhibitor pharmaceutical compositions and methods of use
DE19705450A1 (de) 1997-02-13 1998-08-20 Merck Patent Gmbh Bicyclische aromatische Aminosäuren
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
DE19821003A1 (de) 1998-05-11 1999-11-18 Dresden Arzneimittel Neue 1,2,5-trisubstituierte 1,2-dihydro-indazol-3-one mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AP2001002319A0 (en) 2000-10-26 2001-12-31 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors.
US20060019269A1 (en) 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
PT1572215E (pt) 2002-12-20 2009-12-09 Glaxo Group Ltd Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2006072828A2 (en) 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
WO2006105304A2 (en) 2005-03-31 2006-10-05 Janssen Pharmaceutica N.V. Phenyl and pyridyl lta4h modulators
BRPI0616187A2 (pt) 2005-09-21 2011-06-14 Decode Genetics Ehf composto, composiÇço farmacÊutica, e, uso de uma quantidade terapeuticamente eficaz de um composto
CA2636929A1 (en) 2005-12-21 2007-07-12 Decode Genetics, Ehf Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
WO2007073405A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
TW200823187A (en) 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
WO2011032050A2 (en) * 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Gyrase inhibitors
WO2011114220A1 (en) 2010-03-18 2011-09-22 Biotechnology Research Corporation Limited Neuro-protective effects of adelostemma gracillimum and its isolated compounds
AP3339A (en) * 2011-03-14 2015-07-31 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production
US9139567B2 (en) 2011-07-19 2015-09-22 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase
JP6080226B2 (ja) 2012-03-06 2017-02-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン
AR091315A1 (es) 2012-03-06 2015-01-28 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno
WO2014014874A1 (en) 2012-07-17 2014-01-23 Boehringer Ingelheim International Gmbh Pyrazole derivatives which inhibit leukotriene production

Also Published As

Publication number Publication date
US20150018333A1 (en) 2015-01-15
US9303018B2 (en) 2016-04-05
EP3022193B1 (en) 2017-04-26
WO2015009609A1 (en) 2015-01-22
JP2016525113A (ja) 2016-08-22
EP3022193A1 (en) 2016-05-25

Similar Documents

Publication Publication Date Title
JP6256467B2 (ja) ロイコトリエン生成を阻害するピラゾール誘導体
TWI551593B (zh) 白三烯素生成之苯并二噁烷抑制劑
JP2024045225A (ja) 複素環式化合物、中間体、その製造方法及び応用
ES2459496T3 (es) Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
KR20210013145A (ko) 키나아제 억제제로서 헤테로시클릭 화합물, 헤테로시클릭 화합물을 포함하는 조성물 및 그 사용 방법
KR20140040774A (ko) 이미다조피리딘 화합물
CA2905751A1 (en) Novel compounds and compositions for inhibition of fasn
WO2017066014A1 (en) Bruton's tyrosine kinase inhibitors
ES2976515T3 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
BR112014004631B1 (pt) Derivados de heterociclo bicíclico, seus usos, combinação e composição farmacêuticas
AU2007264791A1 (en) Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use
JPH06145170A (ja) ヘテロ環式化合物、その製法及びこれを含有する高血圧及びうつ血性心不全治療用医薬組成物
AU2021388798A1 (en) Aryl derivatives for treating trpm3 mediated disorders
JP7688242B1 (ja) ３－フェニルプロピルアミン誘導体
TW202122382A (zh) 乙內醯脲衍生物
EP3022193B1 (en) Inhibitors of leukotriene production
KR102600391B1 (ko) 삼중고리형 화합물
TWI924806B (zh) 具有四氫吲哚-1-甲醯胺作為ｂｃｌ-2抑制劑之化合物、包含其之組合物與其之用途
CN113527261B (zh) 吡啶酮或嘧啶酮类衍生物及其制备方法和用途
TWI899220B (zh) 作為trpv4拮抗劑之嘧啶-4(3h)-酮衍生物
JP2024512753A (ja) 新規なジアルコキシナフト［２，３－ｃ］フラン－１（３Ｈ）－オン誘導体およびこれを含む呼吸器疾患またはＳＡＲＳ－ＣｏＶ－２感染症の予防または治療用の薬学的組成物
EP4724443A1 (en) Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase
EP3022194B1 (en) Inhibitors of leukotriene production
KR20230038740A (ko) Cdk9 억제제 및 이의 용도
CA3293795A1 (en) 3-phenylpropylamine derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170712

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180611

R150 Certificate of patent or registration of utility model

Ref document number: 6353899

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250